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Through the histone methyltransferase EZH2, the
Polycomb complex PRC2 mediates H3K27me3 and
is associated with transcriptional repression. PRC2
regulates cell-fate decisions in model organisms;
however, its role in regulating cell differentiation dur-
ing human embryogenesis is unknown. Here, we
report the characterization of EZH2-deficient human
embryonic stem cells (hESCs). H3K27me3 was lost
upon EZH2 deletion, identifying an essential require-
ment for EZH2 in methylating H3K27 in hESCs, in
contrast to its non-essential role in mouse ESCs.
Developmental regulators were derepressed in
EZH2-deficient hESCs, and single-cell analysis
revealed an unexpected acquisition of lineage-
restricted transcriptional programs. EZH2-deficient
hESCs show strongly reduced self-renewal and pro-
liferation, thereby identifying a more severe pheno-
type compared to mouse ESCs. EZH2-deficient
hESCs can initiate differentiation toward develop-
mental lineages; however, they cannot fully differen-
tiate into mature specialized tissues. Thus, EZH2 is
required for stable ESC self-renewal, regulation of
transcriptional programs, and for late-stage differen-
tiation in this model of early human development.INTRODUCTION
Polycomb-group (PcG) proteins are epigenetic repressors of
transcriptional programs and maintain cellular identity during
development, differentiation, and disease (Di Croce and Helin,
2013; Pasini and Di Croce, 2016; Pietersen and van Lohuizen,
2008; Schuettengruber and Cavalli, 2009; Surface et al., 2010).
PcG proteins form two well-characterized and biochemically
distinct chromatin-modifying complexes that are termed Poly-
combRepressive Complex 1 and 2 (PRC1 and PRC2). PRC1 cat-2700 Cell Reports 17, 2700–2714, December 6, 2016 ª 2016 The Au
This is an open access article under the CC BY license (http://creativealyzes histone H2A lysine 119 ubiquitination through the activity
of the E3 ligases RING1A and RING1B (M€uller and Verrijzer,
2009; Wang et al., 2004). PRC2 is composed of the core proteins
EZH2, EED, and SUZ12, together with RBAP46/48 and several
other accessory subunits, and is responsible for catalyzing
di- and trimethylation on histone H3 lysine 27 (H3K27me2/3)
(Cao et al., 2002; Czermin et al., 2002; Kuzmichev et al., 2002;
Margueron and Reinberg, 2011; M€uller et al., 2002). EZH2 is a
SET-domain containing histone methyltransferase and is the
catalytic subunit of PRC2. EED and SUZ12 are required for sub-
strate recognition, complex stability and for promoting the enzy-
matic activity of EZH2 (Cao and Zhang, 2004; Nekrasov et al.,
2005; Pasini et al., 2004; Tie et al., 2007).
Genome-wide studies in mouse and human embryonic stem
cells (ESCs) have shown that PRC2 and H3K27me3 occupy the
promoters of many developmental regulators that are important
for cell differentiation and lineage specification (Azuara et al.,
2006; Bernstein et al., 2006; Boyer et al., 2006; Bracken
et al., 2006; Lee et al., 2006; Mikkelsen et al., 2007; Pan
et al., 2007; Zhao et al., 2007). This distribution of chromatin
marks led to the concept that PRC2 may contribute to the
maintenance of pluripotency by keeping developmental regula-
tors transcriptionally repressed, while enabling the genes to be
rapidly activated upon suitable differentiation cues and stimuli.
Despite a central position within the regulatory framework,
however, PRC2 is dispensable for the maintenance of undiffer-
entiated mouse ESCs, as the deletion of PRC2 components,
including Ezh2, has little effect on their morphology, self-
renewal, or proliferation, although a subset of PRC2 target
genes are modestly derepressed (Chamberlain et al., 2008;
Leeb et al., 2010; Pasini et al., 2007; Riising et al., 2014;
Shen et al., 2008). H3K27me3 levels are globally reduced in
Ezh2-deficient mouse ESCs; however, developmental regula-
tors retain H3K27me3 at their gene promoters and are tran-
scriptionally repressed (Shen et al., 2008). In this context, the
Ezh2 homolog, Ezh1, forms a noncanonical PRC2 complex
that is able to trimethylate H3K27 at target gene promoters
and maintains transcriptional repression through methylation-
dependent and potentially methylation-independent pathways
(Margueron et al., 2008; Shen et al., 2008).thor(s).
commons.org/licenses/by/4.0/).
Figure 1. Targeted Deletion of EZH2 in hESCs
(A) Overview of EZH2 structure and targeting strategy. Exons encoding CXC and SET domains are indicated. The gRNA sequence is underlined and protospacer
adjacent motif highlighted in red. DNA sequence of the deletions in one EZH2–/+ ESC line and one EZH2–/– ESC line is shown for both alleles. Mutation causes
frameshift and premature stop codon. An additional line is shown in Figures S1 and S2.
(legend continued on next page)
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PRC2 deficiency has a more significant impact on mouse
ESCs upon their differentiation, with defects in the repression
of pluripotency networks and in the failure to fully activate differ-
entiation transcriptional programs. This aberrant gene regulation
results in impaired differentiation and proliferation (Chamberlain
et al., 2008; Pasini et al., 2007; Shen et al., 2008). Further under-
scoring the critical role of PRC2 in directing differentiation
programs, all three PRC2 core components (Ezh2, Eed, and
Suz12) are essential for early mouse development, as loss-of-
function mutant embryos initiate but fail to complete gastrulation
and die between embryonic days 7 and 9 (Faust et al., 1995;
O’Carroll et al., 2001; Pasini et al., 2004). The mutant phenotype
is associated with mis-expression of lineage-specifying genes,
decreased cell proliferation and an increased level of apoptosis
(Pasini et al., 2004).
The well-conserved binding profiles of PRC2 components and
H3K27me3 in human ESCs (hESCs) at the promoters of develop-
mental regulators raises the possibility that PRC2 may also have
an important role in controlling hESC pluripotency and differenti-
ation (Gifford et al., 2013; Ku et al., 2008; Pan et al., 2007; Zhao
et al., 2007). Moreover, coordinated changes to the epigenome,
including H3K27me3 localization, occur upon differentiation of
hESCs and are thought to be essential for lineage specification
and memory of cellular identity, as they are in Drosophila and
themouse (Gifford et al., 2013; Xie et al., 2013).However, no func-
tional studies of PRC2 in hESC regulation and early-stage differ-
entiation have been reported to date. Human pluripotent cells
represent a unique model in which to study human development
and provide a platform for producing a source of differentiated
cells relevant for basic and applied research. In addition, mouse
and human ESCs are known to represent different pluripotent
states and may therefore rely on different epigenetic pathways
to confer their ability to self-renew and differentiate (Nichols
and Smith, 2009; Rossant, 2015). Understanding the key epige-
netic mechanisms that underpin hESCs is therefore a priority.
Here, we report the generation and characterization of
EZH2-deficient hESCs. Our findings demonstrate that EZH2 is
required to maintain the transcriptional repression of develop-
mental regulators and for cells to undergo late-stage cell differen-
tiation, thereby revealing thebroadconservationofPRC2 function
in this model of early human development. We also identify unex-
pected human-specific differences such as the essential require-
ment in hESC for EZH2 to maintain PRC2 stability and retain
promoter-localized H3K27me3, which is in contrast to its non-
essential role in mouse ESCs. In addition, self-renewal and prolif-
eration are also perturbed to a greater extent in EZH2-deficient
hESCs, as compared to Ezh2-deficient mouse ESCs. Our study
therefore provides a comprehensive characterization of PRC2(B) mRNA expression levels from RNA-seq data revealing EZH2, EED, and SUZ12
show mean ± SD; n = 3 biological replicates.
(C) Immunofluorescentmicroscopy of colonies from EZH2–/– ESCs and control ES
antibody was raised against a C-terminal epitope of EZH2; similar results we
EZH2 (Figure S2E). OCT4 expression indicates undifferentiated cells within a hES
(D) EZH2, SUZ12, and the main isoform of EED are undetectable in EZH2–/– ESCs
EZH2 transgene. b-ACTIN is the loading control. Mass is in kilodaltons.
(E) H3K27me3 and H3K27me2 levels are reduced to background levels, and H3K
indicates undifferentiated ESCs within the field of view. Arrows point to MEF. Sc
2702 Cell Reports 17, 2700–2714, December 6, 2016function in hESCs, therebyproviding a newplatform to investigate
the role of histone methylation in regulating the genome during
human development and stem cell differentiation.
RESULTS
Targeted Deletion of EZH2 in hESCs
To investigate the role of EZH2 in human pluripotency and differ-
entiation, we used CRISPR/Cas9 to disrupt EZH2 in hESCs.
A guide RNA (gRNA) designed to target an early exon within all
known EZH2 isoforms was nucleofected with Cas9 into the
H9 hESC line (Figures 1A and S1A). Individual colonies were
isolated, expanded, and analyzed by Sanger DNA sequencing.
The efficiency of disrupting the target sequence within the
EZH2 coding region was high, with35% clonal lines containing
amutation on one allele (EZH2–/+). However, no homozygous cell
lines were obtained out of 110 screened lines. This result pro-
vided a first indication that EZH2-deficient hESCs may be
compromised relative to EZH2-containing cells when plated as
single cells at clonal density. To overcome this apparent defect,
we introduced a doxycycline (DOX)-inducible EZH2 transgene
using piggyBac transposition into an EZH2–/+ line and re-tar-
geted the cells with EZH2 gRNA and Cas9 in the presence of
DOX. Using this strategy, we obtained several EZH2 homozy-
gous lines (EZH2–/–; Figures 1A, S1B, and S1C). Once the
EZH2–/– lines were isolated and established, they could be main-
tained without DOX-induced EZH2 expression. Although we
did not detect any indication that the DOX-inducible plasmid
was leaky in the absence of DOX, to rule out the possibility
of low-level EZH2 expression, we transiently transfected
EZH2–/– ESCs with piggyBac transposase and obtained stable
EZH2–/– lines with all copies of the EZH2 transgene removed
(Figures S2A and S2B).
RNA expression analysis confirmed that EZH2 transcripts
were lower in EZH2–/– ESCs compared to parental EZH2+/+
and EZH2–/+ lines (Figures 1B and S2C). Moreover, EZH2 protein
was undetectable by western blot and by immunofluorescent
microscopy using two different antibodies raised against
N- and C-terminal epitopes of EZH2 (Figures 1C, 1D, and
S2D–S2F). The disruption of EZH2 was accompanied by the
loss of other PRC2 proteins, SUZ12 and EED, despite the pres-
ence of unchanged levels of SUZ12 and EED transcripts in
EZH2–/– ESCs (Figures 1B and 1D). This finding unexpectedly
contrasts with Ezh2-deficient mouse ESCs where Suz12 and
Eed levels are unchanged due to the ability of Ezh1 to form non-
canonical PRC2 (Shen et al., 2008) but is consistent with
Suz12-deficient and Eed-deficient mouse ESCs in which PRC2
components are unstable outside of the complex (Pasini et al.,transcript levels in EZH2+/+, EZH2–/+, EZH2–/–, and EZH2–/– +EZH2 ESCs. Data
Cs. This analysis reveals a strong reduction in EZH2 levels in EZH2–/– ESCs. The
re obtained using an alternative antibody raised against the N-terminal of
C colony. Arrows point to MEF. Scale bars, 100 mm.
by western blot analysis and are restored upon expression of a DOX-induced
27me1 levels are partially reduced, in EZH2–/– ESCs. OCT4 expression in inset
ale bars, 100 mm.
Figure 2. EZH2 Deficiency in hESCs Results in Loss of H3K27me3
(A) Quantitative trend plot of H3K27me3 normalized ChIP-seq reads over gene body ±5 kb. High CpG (HCP), intermediate CpG (ICP), and low CpG (LCP)
promoters are shown separately.
(B) Scatterplot of H3K27me3 (x axis) and H3K4me3 (y axis) normalized ChIP-seq reads in EZH2–/– relative to EZH2+/+ (left) and relative to EZH2–/– +EZH2 (center),
and EZH2–/– +EZH2 versus EZH2+/+ (right). All transcriptional start sites (TSS) shown in gray; TSS that are positive for H3K27me3 in EZH2+/+ ESCs highlighted in
blue. Disruption of EZH2 leads to a strong reduction in H3K27me3 levels at TSS, with little effect on H3K4me3 levels. Expression of a DOX-mediated
EZH2 transgene in the EZH2-deficient cells causes restoration of H3K27me3 levels to levels equivalent to EZH2+/+.
(C) ChIP-seq tracks of HOXB (left) and HOXD (right) loci illustrate the loss of H3K27me3 in EZH2–/– ESCs compared to control ESCs. H3K4me3 is relatively
unaffected. All ChIP-seq data represent the average of three biological replicates for each cell line. These results were confirmed independently by qPCR analysis
of ChIP DNA at several gene promoters (Figure S3C).2004, 2007). In hESCs, therefore, EZH1 is unable to form nonca-
nonical PRC2 despite being present (Figure S2G). EZH1 tran-
script and protein levels were largely unchanged upon EZH2
deletion (Figure S2G). Immunofluorescent microscopy revealed
that the loss of EZH2 led to the reduction of H3K27me3 and
H3K27me2 to background levels, and to the partial reduction
of H3K27me1 (Figure 1E). Applying DOX to induce ectopic
EZH2 expression in EZH2–/– ESCs restored EZH2 and led to
the stabilization of SUZ12 and EED proteins, and to the re-estab-
lishment of global H3K27methylation (cells designated herein as
EZH2–/– +EZH2; Figures 1B–1E).Loss of Promoter-Localized H3K27me3 in EZH2-
Deficient hESCs
To characterize the molecular phenotype of EZH2-deficient
hESCs, we profiled genome-wide histone methylation by native
chromatin immunoprecipitation combined with high-throughput
sequencing (chromatin immunoprecipitation sequencing
[ChIP-seq]). Quantitative trend plots of normalized ChIP-seq
reads revealed a complete loss of H3K27me3 at all gene pro-
moters in EZH2–/– ESCs (Figure 2A). This finding contrasts with
the retention of H3K27me3 at the promoters of developmental
regulators in Ezh2-deficient mouse ESCs (Shen et al., 2008).Cell Reports 17, 2700–2714, December 6, 2016 2703
Figure 3. Genes Encoding Developmental Regulators Are Transcriptionally Derepressed in EZH2-Deficient hESCs
(A) RNA-seq heatmap for EZH2–/– ESCs and control ESCs (three biological replicates per line). Shown are all differentially expressed genes between EZH2–/–and
EZH2–/– +EZH2 ESCs.
(legend continued on next page)
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Confirming the result in hESCs, scatterplot analysis of 2,000
promoters that have high levels of H3K27me3 in EZH2+/+ ESCs
(H3K27me3WT) revealed a loss of H3K27me3 in EZH2–/– ESCs
(Figure 2B). The majority of H3K27me3WT promoters have his-
tone H3 lysine 4 trimethylation (H3K4me3) in hESCs (Pan et al.,
2007; Zhao et al., 2007), and H3K4me3 levels were largely unaf-
fected by EZH2 disruption (Figure 2B). ChIP-seq tracks for two
example loci, HOXB and HOXD, illustrate the loss of
H3K27me3 across the domains in EZH2–/– ESCs (Figure 2C).
Comparison of H3K27me3 between EZH2+/+ and
EZH2–/– +EZH2 cells revealed highly similar profiles, demon-
strating that histone patterns are appropriately re-established
upon EZH2 restoration (Figures 2A–2C). Interestingly, there
was a modest increase in histone H3 lysine 27 acetylation
(H3K27ac) levels at H3K27me3WT promoters in EZH2–/– ESCs,
supporting a potential antagonism between H3K27 acetylation
and trimethylation that has also been observed in other contexts
(Ferrari et al., 2014; Gehani et al., 2010; Jung et al., 2010; Pasini
et al., 2010; Schoenfelder et al., 2015) (Figure S3A). Last, an
alternative ChIP-seq analysis strategy of genome binning
confirmed a loss of H3K27me3 sequencing reads across the
genome of EZH2–/– ESCs, further reinforcing the key finding
that H3K27me3 levels are depleted upon deletion of EZH2 in
hESCs (Figure S3B). Together, these results demonstrate that
EZH2 is the main functional H3K27me2/3 methyltransferase in
hESCs.
EZH2 Deficiency Causes Transcriptional Derepression
of Key Developmental Genes
We next performed RNA sequencing (RNA-seq) to investigate
the impact of loss of EZH2 and associated H3K27me3 on gene
expression. The assays were carried out on samples that were
flow-sorted using the hESCs cell-surface marker SSEA4 to
ensure that we compared between equivalent cell populations
(Figure S4A). The majority of genes were not altered transcrip-
tionally by EZH2 disruption, but 911 genes were significantly
upregulated and 282 genes were significantly downregulated
in EZH2–/– ESCs compared to EZH2–/– +EZH2 ESCs (p < 0.05;
Figures 3A and S4B). Gene ontology (GO) analysis of the
upregulated gene set identified categories associated with
developmental and cellular differentiation, including pattern
specification, embryonic morphogenesis, and tissue forma-
tion (Figure 3B). The upregulated group was significantly
enriched for genes with EZH2 and H3K27me3 occupancy
in EZH2+/+ ESCs and are thus expected to be sensitive to(B) Top GO terms of differentially expressed gene sets. Numbers of genes are
p values were calculated using a modified Fisher’s exact test followed by Bonfe
(C) Gene set enrichment analysis of PRC2 targets (n = 1,299; defined by high E
genes that have been ranked according to their fold change in transcription betwe
reveals that genes selectively derepressed in the absence of EZH2 are enriched
(D) Genes within the upregulated category have higher levels of promoter-loca
expression-matched set of genes and to downregulated genes. Data were comp
(E) Genes encoding developmental regulators are transcriptionally derepressed
family groups. The color of each circle represents the log2 fold change in EZH2–
expression value of the gene in EZH2–/– cells. A similar pattern of target gene d
(Figure S4C).
(F) ChIP-seq andmRNA-seq tracks of four genes encoding key developmental reg
upregulation in EZH2–/– ESCs.EZH2 disruption (Figures 3C and 3D). Notably, not all genes
with EZH2-bound promoters were mis-regulated, suggesting
that secondary events may be required for this group of genes
to initiate transcriptional change in response to the loss of
EZH2. In addition, a subset of upregulated genes (enriched for
signaling and adhesion GO terms) are likely to be regulated indi-
rectly as they are not PRC2 targets in hESCs. No GO categories
were significantly enriched in the downregulated gene set,
although of note, the top category was associated with the regu-
lation of M-phase and indicate the decreased transcription of
genes typically expressed in mitosis (Figure 3B).
We examined transcriptional changes in a set of 100 clas-
sical developmental regulators that have strong EZH2 promoter
occupancy, including genes within the FOX, GATA, LHX, T-box,
and SOX families (Lee et al., 2006). A clear pattern emerges
from this analysis: nearly all genes within this class of develop-
mental regulator showed transcriptional derepression in the
absence of EZH2 (Figures 3E and S4C). Gene derepression
did not become more prevalent upon continued passaging,
and therefore the EZH2–/– ESCs retained a similar transcrip-
tional profile over time. ChIP-seq and RNA-seq tracks for
several example genes, including SOX17, GATA4, T, and
TBX3, illustrate the absence of promoter H3K27me3 and
an associated increased transcript level in EZH2–/– ESCs
(Figure 3F). We further showed that small hairpin RNA
(shRNA)-mediated depletion of EZH2 causes derepression of
developmental regulators in two additional human pluripotent
stem cell lines (WIBR3 and FiPS; Figure S4D). We conclude
that the deletion of EZH2 in hESCs leads to the loss of
H3K27me3 and to the transcriptional derepression of genes
that encode developmental regulators, thereby positioning
EZH2 as a key factor in controlling the transcriptome of human
cell types during early development.
Single-Cell Transcriptional Analysis Reveals Gene
Mis-regulation Profiles
To investigate more precisely the transcriptional mis-regulation
and cell-to-cell variability in response to EZH2 deficiency, we
performed single-cell RNA-seq on individual SSEA4-positive,
flow-sorted EZH2–/– and EZH2+/+ ESCs. The results show that
a subset of EZH2–/– ESCs strongly upregulated EZH2-target
genes, but individual genes are not robustly derepressed in
most cells examined (Figure 4A). Unexpectedly, clustering of
the data suggested that gene derepression occurs predomi-
nately within discrete transcriptional programs, such thatshown; example genes within each GO category are listed (right). Corrected
rroni’s multiple comparison test.
ZH2 and H3K27me3 promoter-localized ChIP-seq values in EZH2+/+ ESCs) in
en EZH2–/– ESCs and EZH2–/– +EZH2 ESCs. The positive enrichment score (ES)
in PRC2 targets (p < 0.001; Kolmogorov-Smirnov statistic).
lized EZH2 (upper) and H3K27me3 (lower) in EZH2+/+ ESCs compared to an
ared using a Kruskal-Wallis test followed by Dunn’s multiple comparison test.
in EZH2-deficient ESCs. A subset of direct EZH2 target genes is depicted as
/– ESCs relative to EZH2–/– +EZH2 ESCs. The size of each circle represents the
erepression is observed when comparing EZH2–/– ESCs with EZH2+/+ ESCs
ulators illustrate the association between loss of H3K27me3 and transcriptional
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Figure 4. Transcriptional Derepression Occurs Predominantly within Discrete Lineage-Specific Programs
(A) Single-cell RNA-seq expression levels for six example PRC2-target genes in EZH2–/– ESCs and EZH2+/+ ESCs, where each dot represent the results from a
single cell. A pluripotency gene (LIN28) and housekeeping gene (HMBS) are shown for comparison. Robust upregulation of PRC2-target genes occurs in a subset
of EZH2–/– ESCs.
(B) Heatmap of single-cell RNA-seq expression for EZH2–/– ESCs (right) and EZH2+/+ ESCs (left). Each column represents an individual cell. Each row represents
an individual gene, grouped into three clusters corresponding to endoderm, mesoderm, and ectoderm cell lineages. Shown are PRC2-target genes from within
the hESC scorecard assay, which is an assay that can classify differentiated cell lineages (Bock et al., 2011). Subsets of cells (boxed in purple) tend tomis-express
many genes from within one lineage but rarely mis-express multiple genes derived from more than one lineage.
2706 Cell Reports 17, 2700–2714, December 6, 2016
Figure 5. EZH2-Deficient hESCs Are
Compromised in Self-Renewal and Prolif-
eration
(A) Phase contrast images show representative
colonies of EZH2+/+, EZH2–/–, and EZH2–/– +EZH2
ESC lines. Note the variable morphology of
EZH2-deficient colonies. Scale bars, 100 mm.
(B) EZH2–/– ESCs show reduced ESC colony for-
mation when plated as single SSEA4-positive cells
at low density (6,000 cells seeded per well). Data
show mean ± SD; n = 3 biological replicates.
Data were compared using a one-way ANOVA
followed by Bonferroni’s multiple comparison test
(***p < 0.0005). Representative AP staining is
shown underneath.
(C) EZH2–/– ESCs have reduced capacity to self-
renew when plated at clonal density. ESC colonies
were categorized as undifferentiated, mixed, or
differentiated based on AP activity; examples
shown underneath. Data show mean ± SD; n = 3
biological replicates. Over 150 colonies were
scored for each cell line. Data were compared
using a one-way ANOVA followed by Bonferroni’s
multiple comparison test (***p < 0.0005;
**p < 0.005; *p < 0.05). Scale bars, 100 mm.
(D) Immunofluorescent microscopy for OCT4 (un-
differentiated marker) and SOX17 (early differenti-
ation marker) reveals an increased prevalence for
mixed and fully differentiated colonies in EZH2–/–
compared to control ESC lines. Representative
images are shown underneath. Over 100 colonies
were scored for each cell line. Scale bars, 100 mm.
(E) Growth curve over 16 days reveals a significant
proliferation defect in EZH2–/– ESCs compared to
control ESCs. Data show mean ± SD; n = 3 bio-
logical replicates. Data were compared between
EZH2–/– ESCs and each control ESC line using
one-way ANOVA followed by Bonferroni’s multiple
comparison test (*p < 0.05 for each comparison).
(F) Mitotic index was calculated for each ESC line
by dividing the number of H3S10ph-positive cells
by the total number of cells within a colony. The
analysis was restricted to undifferentiated colonies
(determined by OCT4 expression) of similar size in
order to control for potential differences in cell
state. Over 1,000 cells were scored for each cell
line. Data show mean ± SD; n = 3 biological repli-
cates. Data were compared using a one-way
ANOVA followed by Bonferroni’s multiple com-
parison test (***p < 0.0005). Scale bars, 100 mm.individual EZH2–/– ESCs have upregulated multiple genes asso-
ciated with a particular cell lineage but rarely show strong signa-
tures derived from several cell lineages (Figure 4B). In particular,
EZH2–/– ESCs show lineage biases toward endoderm andmeso-
derm, but not to ectoderm. This responsemay be constrained by
the hESC culture environment due to the activities of FGF and
Activin/Nodal signaling within the media, which are known to
promote endoderm and mesoderm specification and suppress
ectoderm differentiation (Pauklin and Vallier, 2015). Together,
these results reveal that the depletion of EZH2 does not cause
global EZH2-target gene derepression in all ESCs, as might be
predicted from cell population studies. Rather, its loss leads tothe mis-regulation of subsets of genes and to the acquisition of
lineage-restricted transcriptional programs.
EZH2 Disruption Causes Self-Renewal and Proliferation
Defects in hESCs
Undifferentiated EZH2-deficient ESCs could be maintained in
culture for >50 passages; however, their growth andmorphology
were severely compromised compared to control lines. EZH2–/–
colonies were highly variable in appearance with an increased
prevalence of flatter cells that are characteristic of spontaneous
differentiation (Figure 5A). To compare directly the ability of
each hESC line to self-renew, we plated an equal number ofCell Reports 17, 2700–2714, December 6, 2016 2707
(legend on next page)
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SSEA4-positive flow sorted cells at clonal density, and after
7 days we counted the number of colonies that were positive
for the undifferentiated hESC marker alkaline phosphatase
(AP). We observed an 40% reduction in colony number in
EZH2–/– ESCs compared to control ESCs (Figure 5B).
Diminished colony formation was due to both compro-
mised self-renewal and impaired proliferation. Categorizing
EZH2–/– ESC colonies based on AP activity patterns revealed
an50% reduction in the proportion of undifferentiated colonies
in EZH2–/– ESCs compared to control ESCs, and an associated
increase in the proportion of colonies with a mixed or fully differ-
entiated phenotype (Figure 5C). This was accompanied by a
decrease in the proportion of EZH2–/– ESC colonies that are
entirely OCT4 positive, with an associated increase in the pro-
portion of colonies that are positive for SOX17, a marker of early
differentiated cells (Figure 5D). The proportion of undifferentiated
and differentiated cells within the EZH2–/– ESC cultures was un-
changed over passage and was re-established after plating of
purified undifferentiated EZH2–/– ESCs, further highlighting the
unstable nature of these cells.
Cell counts over four passages revealed an50% reduction in
cell number in EZH2–/– ESCs, revealing that proliferation is signif-
icantly reduced in the absence of EZH2 (Figure 5E). The mitotic
index, as determined by the proportion of histone H3 serine
10 phosphorylation (H3S10ph) positive cells, was significantly
lower in EZH2–/– ESCs compared to control ESCs (Figure 5F).
The reduction in mitotic cells within EZH2–/– cultures is in agree-
ment with our RNA-seq results, which identify the transcriptional
downregulation of genes associated with M-phase (Figure 3B).
Of further relevance to this defect is that several negative regula-
tors of the cell cycle, such as CDKN2A (encoding p16INK4A and
p14ARF) and CDKN2B (encoding p15INK4B), were transcrip-
tionally derepressed in EZH2-deficient ESCs (Figure S5). These
findings are consistent with previous studies in other cell types
that have identified a role for EZH2 in controlling the transcription
of cell-cycle regulators (Bracken et al., 2003, 2007; Pasini et al.,
2004; Sauvageau and Sauvageau, 2010; Varambally et al.,
2002). Together, the results demonstrate that EZH2-deficient
hESCs are strongly compromised in their ability to self-renewFigure 6. EZH2-Deficient hESCs Can Initiate Differentiation but Are Se
(A) EZH2–/– ESCs fail to generate teratomas. Mass of teratoma and kidney samp
Additional images and histology analysis are provided in Figures S6A and S6B.
(B) ESCs were induced to differentiate with retinoic acid for 5 days. Cell counts (u
5 days compared to control ESCs. Short bars indicate mean values for the two b
(C) EZH2-deficient ESCs can generate early endoderm cells. Upper panel shows
cytometry analysis of endoderm markers KIT/CXCR4 in undifferentiated EZH2+/+
EZH2–/– ESCs (red), and day 5 endoderm differentiated EZH2–/– (purple). Inset nu
biological replicates, with range).
(D) EZH2-deficient ESCs can generate early mesoderm cells. Upper panel shows
cytometry analysis of mesoderm markers KDR/PDGFRa.
(E) RT-qPCR analysis of endoderm, mesoderm, ectoderm and pluripotency
EZH2+/+ ESCs, and undifferentiated (red) and day 5 endoderm differentiated (purp
differentiation (Loh and Lim, 2011), which may underlie their elevated expression
(F) qRT-PCR analysis of undifferentiated and day 2 mesoderm differentiated ESC
(G) EZH2-deficient ESCs can generate early ectoderm cells, but with significantly
over 10 days of ectoderm differentiation. Lower panel shows flow cytometry analys
significantly decreased efficiency of ectoderm differentiation in EZH2–/– ESCs co
(H) RT-qPCR analysis of undifferentiated and day 10 ectoderm differentiated ESC
compared using an unpaired two-sided t test (*p < 0.05).and proliferate, thereby identifying a more severe phenotype
compared to mouse ESCs that are deficient for Ezh2 and other
PRC2 proteins.
Differentiation Defects in EZH2-Deficient hESCs
Wenext investigated the impact of EZH2 deletion on the ability of
hESCs to differentiate correctly. We injected each hESC line into
the kidney capsule of three immunocompromised mice to test
for teratoma formation. Control hESC lines produced teratomas
consisting of mature cell types derived from all three germ line-
ages. By contrast, EZH2–/– ESCs failed to produce teratomas
in two mice and generated a very small mass in one mouse,
which consisted of a restricted set of cell types, including imma-
ture adipocytes and epithelial cells (Figures 6A, S6A, and S6B).
Although the DOX-inducible EZH2 transgene could partially
rescue the EZH2–/– phenotype, we noticed that the teratomas
formed from the EZH2–/– +EZH2 ESCs were smaller and displayed
differentmorphology compared to theEZH2+/+ andEZH2–/+ ESC
teratomas (Figures 6A, S6A, and S6B). The difference is likely to
be because the cells were not providedwith DOX once they were
injected in situ, and therefore EZH2 levels would be lost gradually
over several days. Further investigation of EZH2 function in late-
stage cell differentiation revealed that very few EZH2–/– ESCs
survived after 5 days of retinoic-acid-mediated differentiation
in vitro, compared to EZH2+/+ and EZH2–/+ ESCs (Figure 6B).
Restoration of EZH2 with the DOX-inducible transgene partially
rescued the defect, although we noticed that the transgene
was silenced at the later stages of cell differentiation, thereby
hindering a full rescue. Together, these results lead us to con-
clude that hESCs require EZH2 to form late-stage differentiated
cell types.
We next studied the early stages of ESC differentiation. PRC2
loss-of-function mutant embryos initiate but fail to complete
gastrulation (Faust et al., 1995; O’Carroll et al., 2001; Pasini
et al., 2004); however, a detailed examination of PRC2-deficient
mouse or human ESC differentiation toward early developmental
progenitors using defined conditions has not been reported. To
investigate these developmental events, we initiated directed
and separate differentiation toward endoderm, mesoderm, andverely Impaired in Generating Mature Cell Types
les for indicated ESC lines, with images shown underneath (scale bar, 5 mm).
pper) and crystal violet stain (lower) reveal that few EZH2–/– ESCs remain after
iological replicates.
cell counts over endoderm differentiation time course. Lower panel shows flow
ESCs (black), day 5 endoderm differentiated EZH2+/+ (blue), undifferentiated
mbers show percentage positive cells for each cell population (mean of three
cell counts over 6 days of mesoderm differentiation. Lower panel shows flow
genes in undifferentiated (black) and day 5 endoderm differentiated (blue)
le) EZH2–/– ESCs. Note thatPOU5F1 andNANOG are also associated with ESC
patterns in EZH2–/– ESCs.
s.
reduced efficiency compared to EZH2+/+ ESCs. Upper panel shows cell counts
is of ectodermmarker CD56 and undifferentiated ESCmarker CD326. Note the
mpared to EZH2+/+ ESCs (p = 0.01; unpaired two-sided t test).
s. For all panels, data showmean ± SEM of three biological replicates and were
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Figure 7. Proposed Model Summarizing the
Role of EZH2 in Regulating Transcriptional
Programs and Cell Differentiation in hESCs
EZH2+/+, above; and EZH2–/–, below. EZH2 defi-
ciency leads to loss of PRC2, transcriptional
derepression of developmental regulators and
self-renewal defects in hESCs. Substantial cell
loss (red crosses) and gene mis-regulation is
observed upon differentiation of EZH2–/– ESCs
(e.g., to endoderm in example shown).ectoderm progenitors, using defined conditions and lineage-
specific markers (Supplemental Experimental Procedures). We
observed that cell number declined sharply during endoderm
and mesoderm differentiation of EZH2–/– ESCs, such that very
fewcells remainedby the endof their differentiation protocols (Fig-
ures 6C and 6D). In contrast, cell number was maintained in
EZH2+/+ ESCs during differentiation. We examined the cells at a
mid-stage time point as this allowed us to obtain sufficient cells
for analysis. Quantitative analysis of lineage-specific, cell-surface
markers using flow cytometry showed that EZH2–/– ESCs
were capable of differentiating into early-stage endoderm
(defined as KIT+/CXCR4+) (Nostro et al., 2011) and mesoderm
(defined as PDGFRa+/KDR+) (Kattman et al., 2011) and, sur-
prisingly, formed cell populations at these time points that
were more uniform in marker expression than achieved upon dif-
ferentiation of EZH2+/+ ESCs (Figures 6C and 6D). To ascertain
whether a pre-existing subset of endoderm progenitors
were responsible for generating endoderm cells in EZH2–/– cul-
tures, we used flow cytometry to separate KIT+/CXCR4+
(endoderm primed) and KIT–/CXCR4– (not endoderm primed)
EZH2–/– populations and subjected the cells to endodermdifferen-
tiation. Flow cytometry analysis showed that KIT–/CXCR4–
were highly efficient in generating endoderm, thereby de-
monstrating the ability of EZH2-deficient ESCs to respond to
appropriate differentiation cuesand initiate early-stage differentia-
tion (Figure S6C).
Upon cell differentiation, pluripotency factors POU5F1,
NANOG, and SOX2 were downregulated to a similar extent in
EZH2–/– ESCs compared to EZH2+/+ ESCs (Figures 6E and 6F).
This finding is in contrast to PRC2-deficient mouse ESCs, which2710 Cell Reports 17, 2700–2714, December 6, 2016exhibit a defect in silencing pluripotency
networks during cell differentiation (Pasini
et al., 2007; Shen et al., 2008). Consistent
with our RNA-seq data, genes associated
with endoderm and mesoderm differenti-
ation were detected at higher levels at
day 0 in EZH2–/– ESCs compared to
EZH2+/+ ESCs, and the transcript level
of these genes increased further during
differentiation, confirming their ability to
undergo early-stage differentiation (Fig-
ures 6E and 6F). Ectopic expression of
lineage-restricted genes occurred during
EZH2–/– ESC differentiation, suggesting
a failure to repress alternate transcrip-
tional programs (Figures 6E and 6F).EZH2-deficient cellswere also able to generate early ectoderm
cells (defined as CD56+/CD326–) (Gifford et al., 2013); however,
cell number during differentiation and the efficiency of differenti-
ationwere significantly reduced compared toEZH2+/+ ESCs (Fig-
ure 6G).Mis-regulation of lineage-restricted geneswas observed
upon ectoderm differentiation, thereby identifying a requirement
for EZH2 in regulating appropriate gene expression in the early
stages of ectoderm specification (Figure 6H).
Taken together, these results demonstrate that EZH2 is not
required for the initial phase of hESC differentiation but is
required for the robust generation of mature cell types that are
produced in the later stages of differentiation in vitro or in tera-
toma assays.
DISCUSSION
PcG-proteins are essential regulators of cell-fate decisions and
transcriptional programs during the development of several spe-
cies, including Drosophila and the mouse. Here, we show that
this important function is also required in humans during the
establishment of early developmental cell types that arise upon
ESCdifferentiation (Figure 7). Furthermore, loss of EZH2 function
in undifferentiated hESCs led to the transcriptional derepression
of 900 genes including many important developmental regula-
tors, thereby positioning EZH2 as a key factor in controlling the
transcriptome of human cell types during early development.
Interestingly, not all PRC2-target genes were mis-regulated,
suggesting that redundant modes of transcriptional repression
are in place, or that additional cues (such as transcription factor
binding) are required to fully activate those genes. In addition to
developmental factors, we also detected an increased expres-
sion of cell-cycle regulators in the absence of EZH2, including
CDKN2A (encoding p16INK4A and p14ARF) and CDKN2B (en-
coding p15INK4B). Given the close association between cell-cy-
cle control and cell differentiation in hESCs (Pauklin and Vallier,
2013; Gonzales et al., 2015; Pauklin et al., 2016), it is likely that
both processes contribute to the phenotype of EZH2-deficient
cells. For example, an upregulation of p16INK4A would inhibit
CDK4/6, which, in turn, would lead to an increase in Activin/
Nodal activity (Pauklin and Vallier, 2013). This signaling change
would promote the transcriptional programs of endoderm and
mesoderm lineages and suppress ectoderm differentiation. We
speculate, therefore, that the increased expression of endoderm
and mesoderm genes in EZH2-deficient hESCs is caused jointly
by the removal of repressive H3K27me3 marks, by altered
signaling activities that are mediated by cell-cycle machinery,
and by the cell-culture environment. Notably, our transcriptional
results are consistent with a recent study that reported derepres-
sion of a subset of PRC2-target genes in Ezh2-deficient mouse
epiblast tissue, thereby underscoring the relevance of our obser-
vations to pluripotent cells in vivo (Zylicz et al., 2015). Impor-
tantly, our analysis of individual cells further revealed that mis-
regulation of genes tended to occur in a coordinated manner
within lineage-restricted transcriptional programs, rather than a
haphazard derepression of all PRC2-target genes as might be
predicted from global cell population analysis. These results
suggest the presence of feedback mechanisms that are able to
promote or repress alternative cell fates during the early phases
of differentiation. An exciting set of future studies will be tomodel
and investigate the mechanisms responsible for this feedback.
Our findings also raise broader questions about how cells are
committed to a particular lineage during differentiation. Purifying
live hESC populations that are in different transcriptional states
and challenging the cells to functional assays should begin to un-
ravel the complexities of cell-fate commitment during human
development.
Despite extensive conservation in their functions, differences
exist between mouse and human ESCs that lack EZH2; self-
renewal, morphology, and proliferation are seemingly perturbed
to a greater extent in human EZH2–/– ESCs compared to mouse
Ezh2–/– ESCs (Shen et al., 2008). One potential explanation is
that differences in PRC2 protein stability or function could
contribute to the distinct mouse and human ESC phenotypes.
For example, Eed and Suz12 levels are unaffected by the loss
of Ezh2 inmouse ESCs, potentially due to a partial compensation
by Ezh1 (Shen et al., 2008). In contrast, we show here that deple-
tion of EZH2 in hESC results in loss of EED and SUZ12, despite
the presence of EZH1. Interestingly, Ezh1 cannot compensate
for the absence of Ezh2 during mouse ESC differentiation or em-
bryo gastrulation (O’Carroll et al., 2001; Shen et al., 2008). We
speculate there is a context-dependent role for Ezh1 and that
the compensatory function diminishes as cells enter the post-im-
plantation phase of development, which could partially explain
the apparent inability of EZH1 to fulfill a compensatory role in
EZH2-deficient hESCs. In addition, Ezh1 is able to repress
gene transcription through methylation-independent mecha-
nisms in somatic cells, potentially via chromatin compaction
(Margueron et al., 2008). It will therefore be interesting in futurestudies to more precisely define the functional interplay between
EZH1 and EZH2 in early human developmental cell types.
A second potential explanation for the distinct phenotypes is
that mouse and human ESCs are known to represent different
pluripotent states, with hESCs considered to be primed for
differentiation (Nichols and Smith, 2009; Rossant, 2015). The
EZH2-deficient phenotype may therefore manifest differently
depending on cell state, a concept recently proposed for
DNMT1-depleted ESCs (Liao et al., 2015). It will be important
in future studies to test this hypothesis by investigating the role
of PRC2 in human ‘‘naive’’ pluripotent cells, which are reported
to be more similar to mouse ESCs (Manor et al., 2015). Further-
more, it is interesting to consider that PRC2 may contribute to
the balance required for primed-state pluripotency by enabling
low-level expression of lineage-specifying developmental regu-
lators while constraining their levels so that they do not over-
whelm the maintenance of the undifferentiated state. Given
that the ectopic expression of several EZH2 target genes, such
as SOX17 and GATA6, can induce the differentiation of hESC
(Se´guin et al., 2008; Wamaitha et al., 2015), it is plausible that
derepression of these and other developmental regulators in
the absence of EZH2 results in a shift toward an increased level
of spontaneous differentiation that is observed in EZH2-deficient
hESCs. Thus, our analysis of PcG function in hESCs should lead
to a better understanding of the processes that regulate lineage
priming and cell-fate commitment and inform similar events that
occur in other species and cell types.
Genome-wide mapping has revealed that dynamic changes in
epigenetic marks, including H3K27me3 localization, occur upon
hESC differentiation (Gifford et al., 2013; Xie et al., 2013). A pre-
vailing model proposes that this epigenetic reconfiguration is
required to coordinate transcriptional programs and provide a
memory of cell identity. We have now tested this model, and
we show that EZH2 is not required for the initial phase of hESC
differentiation as ectoderm, mesoderm, and endoderm germ lin-
eages can form in the absence of EZH2; however, the mutant
cells mis-express lineage-specific genes are unstable and are
gradually lost over the differentiation time course. Interestingly,
and in contrast to PRC2-deficient mouse ESCs (Pasini et al.,
2007; Shen et al., 2008), pluripotency genes were downregu-
lated appropriately upon differentiation of EZH2-deficient
hESCs, suggesting that these genes are silenced by PRC2-inde-
pendent pathways. The observed differentiation defects and
reduction in cell survival are therefore unlikely to be caused by
aberrant expression of pluripotency factors, but rather by mis-
expression of lineage-specifying genes and cell-cycle regula-
tors. Finally, although the EZH2-deficient hESCs were unable
to form mature cell types, the rescue of early differentiation
defects by conditionally restoring EZH2 levels should enable
the role of PRC2 to be investigated during late-stage in vitro dif-
ferentiation. As the EZH2–/– +EZH2 cells could not fully recapitu-
late the parental wild-type cells in the teratoma and the RA-dif-
ferentiation experiments, alternative conditional systems might
be better suited for the investigation of EZH2 in late-stage cell
differentiation. Interestingly, the results from our teratoma exper-
iments suggest that once the EZH2–/– ESCs have overcome the
initial early-stage differentiation barrier (enabled by residual
EZH2), they are able to specialize along certain tissue lineages.Cell Reports 17, 2700–2714, December 6, 2016 2711
The differences in morphology and tissue composition of the ter-
atomas are presumably, to some extent, a reflection of what dif-
ferentiation pathways are accessible to EZH2-deficient cells.
Future studies using alternative conditional strategies and
more precise differentiation systems should lead to a better un-
derstanding of epigenetic modifiers in the generation of special-
ized cell types. Artificially controlling EZH2 levels may also have
useful practical applications in producing desired cell types, as
has been demonstrated recently to boost production of beta
cell progenitors (Xu et al., 2014).
Taken together, our study provides a comprehensive exami-
nation of EZH2 function in hESC pluripotency and differentiation.
Of note is that PRC2 mediates the self-renewal and differentia-
tion of adult stem cells and cancer stem cells (Sauvageau and
Sauvageau, 2010). Our findings therefore not only reveal the
role of epigenetic modifiers and associated histone marks in
regulating the genome during early human development, but
also establish general principles that can be applicable to stem
cells involved in homeostasis and disease.
EXPERIMENTAL PROCEDURES
Cell Culture
hESCs (H9/WA09, obtained from WiCell; WIBR3, kindly provided by Rudolph
Jaenisch; FiPS, kindly provided by Austin Smith) were cultured at 37C in 5%
CO2 in air on CF1 irradiated mouse embryonic fibroblasts (MEFs) in Advanced
DMEM containing 20% knockout serum replacement supplemented with
2 mM L-glutamine, 0.1 mM b-mercaptoethanol, 1 3 penicillin/streptomycin,
1 3 non-essential amino acids (all from Thermo Fisher Scientific) and
4 ng/ml FGF2 (WT-MRC Cambridge Stem Cell Institute). Where indicated,
DOX was added at 1 mg/ml. For feeder-free culture, ESCs were transferred
onto Vitronectin matrix in TeSR-E8 media (STEMCELL Technologies).
Authentication of the hESCs was achieved by confirmation of expression of
pluripotency gene and protein markers. Cells were routinely verified as
mycoplasma-free using a PCR-based assay. Teratoma formation assays
were performed in a designated facility under licenses granted by the UK
Home Office. Additional cell-culture materials and methods are detailed in
Supplemental Experimental Procedures.
Targeted Deletion of EZH2
EZH2 gRNA (CCGCTTCTGCTGTGCCCTTATC) was designed using http://
crispr.mit.edu (Hsu et al., 2013). The gRNA sequence was incorporated into
the U6 target gRNA expression vector (Mali et al., 2013) and synthesized as
a gBlock by Integrated DNA Technologies. The EZH2 gRNA gBlock was
sub-cloned into pCR2.1-TOPO (Thermo Fisher Scientific) and verified by
sequencing. hESCs were dissociated into single cells using Accutase (Thermo
Fisher Scientific). H9 ESCs (2 million) were nucleofected with 5 mg pCas9_GFP
(Addgene plasmid # 44719) and 5 mg EZH2 gRNA expression vector. After
48 hr, 10,000 GFP-positive single cells were isolated by FACS and seeded
onto MEF in a 10-cm tissue culture dish in ESC media supplemented with
10 mMRho Kinase inhibitor (Cell Guidance Systems) for the first 24 hr. Individ-
ual clones were picked and expanded in 24-well plates. Mutations were vali-
dated by DNA sequencing of TOPO cloned PCR products. As a check for
specificity, ten predicted off-target gRNA sites within genes were tested and
verified to contain unmodified sequences.
Plasmid Constructs
To construct PB-TET-EZH2-ires-mCherry plasmid, the EZH2 coding
sequence was amplified using primers EZH2_attb_F and EZH2_attb_R and
sub-cloned into PB-TET-ires-mCherry plasmid. To generate EZH2–/– +EZH2
ESCs, EZH2–/+ ESCs were lipofected with 1 mg PB-TET-EZH2-ires-mCherry,
1 mg pCAG-rtTA-Puro, and 2 mg pCyL43 (Wang et al., 2008) followed by selec-
tion with 1 mg/ml Puromycin.2712 Cell Reports 17, 2700–2714, December 6, 2016To remove PB-TET-EZH2-ires-mCherry, DOX-induced EZH2–/– +EZH2
ESC were nucleofected with 5 mg pCMV-hyPBase (Yusa et al., 2011)
and 1 mg Turbo-GFP (Lonza). After 48 hr, 10,000 GFP/mCherry double-
positive single cells were isolated by FACS and seeded onto MEFs in a
10-cm tissue culture dish in ESC media supplemented with 10 mM Rho
Kinase inhibitor for the first 24 hr. Individual clones were picked
and expanded in 24-well plates. DNA was genotyped using mCherry_Geno
and TET-Prom_Geno primers to confirm removal of PB-TET-EZH2-ires-
mCherry.
Statistics
For Figure 3D, the data are significantly departed from normality (p < 0.05;
D’Agostino-Pearson omnibus normality test) and the variance is different be-
tween the groups (p < 0.05; Brown-Forsythe test); therefore, a non-parametric
test was used. For statistical analysis of data within Figures 5 and 6, the scatter
of the data lead us to assume that the samples comes from a normally distrib-
uted population and that the variability between the groups is about the same;
therefore, parametric tests were used.
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